Hormone Therapy and Stroke Risk

Does menopausal hormone therapy increase stroke risk?

Oral estrogen-containing therapy has been associated with a small increase in ischemic stroke, most evident in older women and women many years past menopause. In a healthy woman in her early fifties, whose baseline risk is low, the absolute increase is small.

This is why the relative-versus-absolute distinction matters so much. A given percentage increase applied to a low baseline risk produces a small number of additional events; the same increase applied to a high baseline risk produces a much larger one. Your own baseline — blood pressure, smoking, diabetes, atrial fibrillation, prior events — largely determines what the number means for you.

Does the route of estrogen matter?

It appears to. Non-oral estrogen avoids first-pass liver metabolism and its effects on clotting factors, and observational evidence suggests a more favourable vascular profile for transdermal delivery than for oral estrogen at equivalent symptom control.

Because that evidence is largely observational rather than from head-to-head randomized comparison, it is a reasoned clinical preference rather than a proven ranking. Assuming that all estrogen products carry identical risk, however, is clearly wrong.

Progestogen type may also matter for vascular and breast outcomes, and low-dose vaginal estrogen used for genitourinary symptoms is a local treatment with minimal systemic absorption — a different question altogether.

How do age and timing affect the picture?

Risk rises with age and with years since menopause. Guidance generally regards the balance as more favourable for symptomatic women under 60 or within about ten years of menopause, and less favourable for initiation at older ages.

That is a starting framework, not a rule that overrides individual history. Prior stroke, transient ischemic attack, uncontrolled hypertension, active clotting disorders or smoking change the calculation substantially.

What if I have migraine with aura?

Migraine with aura carries its own modest association with ischemic stroke in women, so it is a reason to individualize carefully — address smoking and blood pressure, prefer a steady low-dose non-oral route if hormone therapy is used, and involve a clinician comfortable with both conditions.

Note the distinction from contraception: combined hormonal contraceptives use considerably higher estrogen doses and are generally avoided with aura. Menopausal doses are lower, and the decision is made on its own terms.

What reduces stroke risk more than any hormone decision?

Blood pressure control above all, then not smoking, regular physical activity, treating atrial fibrillation, managing diabetes and cholesterol, moderating alcohol, and treating sleep apnea.

For most midlife women, these levers move stroke risk far more than the choice about hormone therapy does. If you take one action after reading this page, get your blood pressure measured properly.